New Peptide Powerhouses — Brain Cancer, Obesity & AI Design!

ByLab Lurker

1. JM2: Precision Attack on Glioblastoma Stem Cells

Virginia Tech researchers unveiled a synthetic peptide called JM2 that selectively targets glioblastoma stem cells—the root of recurrence in the most deadly brain cancer—as early as May 2025 Virginia Tech News+1Wikipedia+1.

In preclinical models, JM2 disrupted stem-cell-driven tumor regrowth, suggesting a future “maintenance” therapy post standard treatment. This could redefine our approach: not just attacking the tumor, but preventing its return.

2. Macrocyclic Tau Peptides: Tools and Therapies for Neurodegeneration

Late May 2025 reviews in Nature Reviews Chemistry/Chemistry spotlight novel macrocyclic tau-mimicking peptides, innovation tools that mimic pathological tau folds—offering both diagnostic insight and avenues for therapeutic disruption Nature.

These peptides don’t just help identify tau pathology; they potentially block it, marking a leap forward in tackling tauopathies like Alzheimer’s with molecular precision.

3. AI Supercharging Peptide Design: CreoPep & Beyond

  • CreoPep, introduced in May 2025, uses a blend of masked language models and biophysical screening to generate peptides (e.g., conotoxins) with sub-micromolar potency—confirmed by functional assays GlobeNewswire+5Nature+5Drug Target Review+5arXiv+2arXiv+2arXiv+2. It pushes the frontier of machine-led peptide innovation:
    • Leverages FoldX-based energetics
    • Outputs non-natural disulfide-free structures
    • Has real-world lab validation
  • Other platforms like PepGB and PepTune are now solving multi-objective optimization—balancing binding, solubility, and permeability—all within a single generative model arXivDrug Target Review+3arXiv+3arXiv+3Drug Target Review+2Wikipedia+2Investors+2arXiv+1arXiv+1.
  • Bottom line: AI + wet lab = soft-launch assembly line for novel therapeutics—no longer just pipetting, but programming.

4. Mazdutide & Cotadutide: Peptide Duos Crushing Metabolism

Mazdutide (GLP‑1 + glucagon dual agonist) achieved clinically meaningful weight loss in Phase III Chinese trials and gained approval in China by June 2025 Nature+2U.S. Food and Drug Administration+2PsychiatryOnline+2barrons.com+6Wikipedia+6Wikipedia+6. It’s a once-weekly injection that fine-tunes metabolism with surgical precision.

Cotadutide, another dual agonist (GLP‑1 + glucagon), remains in Phase II but continues to show strong metabolic improvement promising for future global rollout WikipediaWikipedia.

These aren’t your grandma’s peptides—they’re metabolic game-changers.

Join the Conversation

Got questions or insights about this topic? Drop a comment on our Facebook Page at AmiPeps Lab-Notes . Need vetted research compound sources or tools? Find them HERE.

Similar Posts